Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era

IF 13.4 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

Nano Convergence Pub Date : 2024-01-11 DOI:10.1186/s40580-023-00410-5

Young Jun Kim, Junhong Min

{"title":"Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era","authors":"Young Jun Kim, Junhong Min","doi":"10.1186/s40580-023-00410-5","DOIUrl":null,"url":null,"abstract":"<div><p>The unprecedented threat of the highly contagious virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes exponentially increased infections of coronavirus disease 2019 (COVID-19), highlights the weak spots of the current diagnostic toolbox. In the midst of catastrophe, nanobiosensors offer a new opportunity as an alternative tool to fill a gap among molecular tests, rapid antigen tests, and serological tests. Nanobiosensors surpass the potential of antigen tests because of their enhanced sensitivity, thus enabling us to see antigens as stable and easy-to-access targets. During the first three years of the COVID-19 pandemic, a substantial number of studies have reported nanobiosensors for the detection of SARS-CoV-2 antigens. The number of articles on nanobiosensors and SARS-CoV-2 exceeds the amount of nanobiosensor research on detecting previous infectious diseases, from influenza to SARS-CoV and MERS-CoV. This unprecedented publishing pace also implies the significance of SARS-CoV-2 and the present pandemic. In this review, 158 studies reporting nanobiosensors for detecting SARS-CoV-2 antigens are collected to discuss the current challenges of nanobiosensors using the criteria of point-of-care (POC) diagnostics along with COVID-specific issues. These advances and lessons during the pandemic pave the way for preparing for the post-COVID era and potential upcoming infectious diseases.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":712,"journal":{"name":"Nano Convergence","volume":"11 1","pages":""},"PeriodicalIF":13.4000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://nanoconvergencejournal.springeropen.com/counter/pdf/10.1186/s40580-023-00410-5","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Convergence","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1186/s40580-023-00410-5","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

The unprecedented threat of the highly contagious virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes exponentially increased infections of coronavirus disease 2019 (COVID-19), highlights the weak spots of the current diagnostic toolbox. In the midst of catastrophe, nanobiosensors offer a new opportunity as an alternative tool to fill a gap among molecular tests, rapid antigen tests, and serological tests. Nanobiosensors surpass the potential of antigen tests because of their enhanced sensitivity, thus enabling us to see antigens as stable and easy-to-access targets. During the first three years of the COVID-19 pandemic, a substantial number of studies have reported nanobiosensors for the detection of SARS-CoV-2 antigens. The number of articles on nanobiosensors and SARS-CoV-2 exceeds the amount of nanobiosensor research on detecting previous infectious diseases, from influenza to SARS-CoV and MERS-CoV. This unprecedented publishing pace also implies the significance of SARS-CoV-2 and the present pandemic. In this review, 158 studies reporting nanobiosensors for detecting SARS-CoV-2 antigens are collected to discuss the current challenges of nanobiosensors using the criteria of point-of-care (POC) diagnostics along with COVID-specific issues. These advances and lessons during the pandemic pave the way for preparing for the post-COVID era and potential upcoming infectious diseases.

Graphical Abstract

查看原文本刊更多论文

COVID-19 大流行期间纳米生物传感器的进展以及后 COVID 时代的未来展望。

传染性极强的病毒--严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）--造成 2019 年冠状病毒病（COVID-19）感染呈指数级增长，这种前所未有的威胁凸显了当前诊断工具箱的薄弱环节。在这场灾难中，纳米生物传感器提供了一个新的机会，作为一种替代工具，填补了分子检测、快速抗原检测和血清学检测之间的空白。纳米生物传感器因其更高的灵敏度而超越了抗原检测的潜力，从而使我们能够将抗原视为稳定且易于获取的目标。在 COVID-19 大流行的头三年，大量研究报告了用于检测 SARS-CoV-2 抗原的纳米生物传感器。有关纳米生物传感器和 SARS-CoV-2 的文章数量超过了以前检测传染病（从流感到 SARS-CoV 和 MERS-CoV）的纳米生物传感器研究数量。这种前所未有的发表速度也意味着 SARS-CoV-2 和当前流行病的重要性。在本综述中，收集了 158 篇报道用于检测 SARS-CoV-2 抗原的纳米生物传感器的研究报告，讨论了纳米生物传感器目前面临的挑战，这些挑战采用的是护理点 (POC) 诊断的标准，同时还涉及 COVID 的特定问题。这些进展和大流行期间的经验教训为后 COVID 时代和即将到来的潜在传染病做好了准备。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nano Convergence Engineering-General Engineering

CiteScore

15.90

自引率

2.60%

发文量

审稿时长

13 weeks

期刊介绍： Nano Convergence is an internationally recognized, peer-reviewed, and interdisciplinary journal designed to foster effective communication among scientists spanning diverse research areas closely aligned with nanoscience and nanotechnology. Dedicated to encouraging the convergence of technologies across the nano- to microscopic scale, the journal aims to unveil novel scientific domains and cultivate fresh research prospects. Operating on a single-blind peer-review system, Nano Convergence ensures transparency in the review process, with reviewers cognizant of authors' names and affiliations while maintaining anonymity in the feedback provided to authors.